Impact of Culture-Positive Preservation Fluid on Early Morbidity and Mortality After Lung Transplantation.
ICU morbidity
antibiotic prophylaxis
lung transplantation
preservation fluid
survival
Journal
Transplant international : official journal of the European Society for Organ Transplantation
ISSN: 1432-2277
Titre abrégé: Transpl Int
Pays: Switzerland
ID NLM: 8908516
Informations de publication
Date de publication:
2023
2023
Historique:
received:
09
08
2022
accepted:
24
01
2023
entrez:
27
2
2023
pubmed:
28
2
2023
medline:
3
3
2023
Statut:
epublish
Résumé
The prevalence, risk factors and outcomes associated with culture-positive preservation fluid (PF) after lung transplantation (LT) are unknown. From January 2015 to December 2020, the microbiologic analyses of PF used to store the cold ischaemia-placed lung graft(s) of 271 lung transplant patients were retrospectively studied. Culture-positive PF was defined as the growth of any microorganism. Eighty-three (30.6%) patients were transplanted with lung grafts stored in a culture-positive PF. One-third of culture-positive PF were polymicrobial. Staphylococcus aureus and Escherichia coli were the most frequently isolated microorganisms. No risk factors for culture-positive PF based on donor characteristics were identified. Forty (40/83; 48.2%) patients had postoperative pneumonia on Day 0 and 2 (2/83; 2.4%) patients had pleural empyema with at least one identical bacteria isolated in culture-positive PF. The 30-day survival rate was lower for patients with culture-positive PF compared with patients with culture-negative PF (85.5% vs. 94.7%,
Identifiants
pubmed: 36846604
doi: 10.3389/ti.2023.10826
pii: 10826
pmc: PMC9945515
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
10826Informations de copyright
Copyright © 2023 Tran-Dinh, Tir, Tanaka, Atchade, Lortat-Jacob, Jean-Baptiste, Zappella, Boudinet, Castier, Mal, Mordant, Ben Abdallah, Bunel, Messika, Armand-Lefèvre, Grall and Montravers.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Clin Infect Dis. 2016 Sep 1;63(5):e61-e111
pubmed: 27418577
Am J Transplant. 2008 Nov;8(11):2420-5
pubmed: 18925908
Transplantation. 2012 May 27;93(10):1058-63
pubmed: 22531492
J Clin Microbiol. 2020 Jun 24;58(7):
pubmed: 32350045
J Thorac Dis. 2019 Sep;11(Suppl 14):S1810-S1816
pubmed: 31632758
Infect Control Hosp Epidemiol. 2012 Jul;33(7):672-80
pubmed: 22669228
Transplant Proc. 2009 Jul-Aug;41(6):2169-71
pubmed: 19715863
Int J Infect Dis. 2020 Jun;95:326-331
pubmed: 32179139
Eur J Clin Microbiol Infect Dis. 2021 Oct;40(10):2227-2234
pubmed: 33733394
Liver Transpl. 2006 Aug;12(8):1253-9
pubmed: 16724336
Clin Microbiol Infect. 2019 May;25(5):595-600
pubmed: 30659919
Eur Respir J. 2017 Sep 10;50(3):
pubmed: 28890434
Clin Transplant. 2019 Sep;33(9):e13589
pubmed: 31077619
J Heart Lung Transplant. 2007 Dec;26(12):1229-42
pubmed: 18096473
J Heart Lung Transplant. 2016 Apr;35(4):397-406
pubmed: 27044531
J Infect. 2020 Feb;80(2):190-196
pubmed: 31843689
J Heart Lung Transplant. 2015 Feb;34(2):189-94
pubmed: 25447581
J Heart Lung Transplant. 2021 Oct;40(10):1060-1072
pubmed: 34446355
Transplant Rev (Orlando). 2018 Apr;32(2):85-91
pubmed: 29275111
Open Forum Infect Dis. 2019 Apr 26;6(6):ofz180
pubmed: 31198815
J Heart Lung Transplant. 2017 Oct;36(10):1097-1103
pubmed: 28942784
Am J Health Syst Pharm. 2013 Feb 1;70(3):195-283
pubmed: 23327981
Eur Respir Rev. 2020 Jul 21;29(157):
pubmed: 32699023
Am J Transplant. 2006 Jan;6(1):178-82
pubmed: 16433772
Clin Microbiol Infect. 2021 Sep;27(9):1308-1314
pubmed: 33276137
Liver Transpl. 2003 May;9(5):451-62
pubmed: 12740786
J Heart Lung Transplant. 2011 Apr;30(4):361-74
pubmed: 21419994
Infection. 2008 Jun;36(3):207-12
pubmed: 18470477